Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891504 | 0.89 | ALDH1A1 (0.35) | ALDH1A1KDM4ECYP1A2KMT2ALMNA | |
| SCHEMBL16480385 | 0.77 | ALDH1A1 (0.42) | ALDH1A1KDM4ECYP1A2KMT2AFKBP1A | |
| SCHEMBL14436592 | 0.76 | TP53 (0.35) | ALDH1A1KMT2ALMNACYP2C19 | |
| SCHEMBL14926818 | 0.76 | TP53 (0.35) | ALDH1A1KMT2ALMNACYP2C19 | |
| SCHEMBL9893174 | 0.75 | TP53 (0.46) | ALDH1A1KDM4ECYP1A2KMT2AFKBP1A | |
| SCHEMBL9103345 | 0.72 | FKBP1A (0.47) | ALDH1A1KDM4ECYP1A2KMT2AFKBP1A | |
| SCHEMBL9103351 | 0.72 | FKBP1A (0.47) | ALDH1A1KDM4ECYP1A2KMT2AFKBP1A | |
| SCHEMBL9917271 | 0.71 | HSD11B1 (0.35) | ALDH1A1KMT2ALMNA | |
| SCHEMBL13986068 | 0.70 | S1PR1 (0.43) | ALDH1A1KDM4EFKBP1A | |
| SCHEMBL4601664 | 0.70 | CASP3 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 3279/4885KDM4E 2527/4885CYP1A2 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.